A 20 000-person study of eicosapentaenoic acid supplements gave solid scientific support for EPA use to prevent cardiovascular events among patients with established coronary artery disease. Mitsuhiro Yokoyama of Kobe University told us more about it.
[audio:https://www.audiomedica.com/podcasting/aha2005/Mitsuhiro_Yokoyama.mp3]
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
Atrial fibrillation is prevented by exercise and life-long endurance athletes do not face the same elevated risks of stroke and heart disease from...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AudioMedica News Young adults less likely to be diagnosed with hypertension than over 60s Play Episode Pause Episode Mute/Unmute Episode Rewind 10...
